HYPEBEAST(00150.HK)首三财季整体收益按年跌22.8%至4.7亿元
HYPEBEAST(00150.HK)公布,截至去年底止首三财季,整体收益按年减少约22.8%至4.73亿元。期内,毛利率保持稳定,约为49.4%。销售及营销开支减少约42.2%至7,820万元;行政及经营开支按年减少8.9%至8,550万元。
总括而言,由於COVID-19相关的全球封锁逐步解除,媒体合约签约量增加及实体活动执行预期增长,管理层预计媒体合约执行及收入推动因素将在未来季度加速增长。管理层预计随着区域扩张和客户获取活动的恢复,电子商务分部将持续发展。管理层因COVID-19 的不确定性而对二零二零秋冬季存货采购量所作出的一次性风险管理调整亦将恢复正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.